Rigel Pharmaceuticals, Inc. (RIGL)
NASDAQ: RIGL · Real-Time Price · USD
37.93
+0.29 (0.77%)
At close: Jan 22, 2026, 4:00 PM EST
38.72
+0.79 (2.08%)
After-hours: Jan 22, 2026, 7:02 PM EST
Rigel Pharmaceuticals Employees
As of December 31, 2024, Rigel Pharmaceuticals had 164 total employees, including 162 full-time and 2 part-time employees. The number of employees increased by 17 or 11.56% compared to the previous year.
Employees
164
Change (1Y)
17
Growth (1Y)
11.56%
Revenue / Employee
$1,719,976
Profits / Employee
$690,854
Market Cap
688.48M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2024 | 164 | 17 | 11.56% | 162 | 2 |
| Dec 31, 2023 | 147 | -8 | -5.16% | 147 | 0 |
| Dec 31, 2022 | 155 | -10 | -6.06% | 155 | 0 |
| Dec 31, 2021 | 165 | -4 | -2.37% | 165 | 0 |
| Dec 31, 2020 | 169 | 6 | 3.68% | 169 | 0 |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| REGENXBIO | 353 |
| Prime Medicine | 214 |
| ProKidney | 204 |
| Vor Biopharma | 159 |
| Cullinan Therapeutics | 111 |
| Invivyd | 100 |
| enGene Holdings | 82 |
| Astria Therapeutics | 78 |
RIGL News
- 7 days ago - Rigel Pharmaceuticals, Inc. (RIGL) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript - Seeking Alpha
- 10 days ago - Rigel Provides Business Update and 2026 Outlook - PRNewsWire
- 13 days ago - Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - PRNewsWire
- 15 days ago - Rigel to Present at the 44th Annual J.P. Morgan Healthcare Conference - PRNewsWire
- 21 days ago - Rigel Pharma: Formulating A Game Plan For 2026 - Seeking Alpha
- 6 weeks ago - Rigel Presents Updated Data from the Ongoing Phase 1b Study Evaluating R289 in Patients with Lower-Risk MDS at the 67th ASH Annual Meeting and Exposition - PRNewsWire
- 2 months ago - Rigel Pharma: Q3 Earnings Showcase Robust Growth - Seeking Alpha
- 2 months ago - Rigel to Present at the Piper Sandler 37th Annual Healthcare Conference - PRNewsWire